| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alignment of Competencies to Address Inefficiencies in Medicines Development and Clinical Research: Need for Inter-Professional Education
|
Silva, Honorio
|
|
2015
|
|
3 |
p. 131-140
|
artikel
|
| 2 |
Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch (Eds). Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies
|
Camastra, Stefania
|
|
2016
|
|
3 |
p. 165-167
|
artikel
|
| 3 |
An Investigation of Physicians’ Perception of Pharmaceutical Trade Names in Jordan’s Private Sector Using Real-World and Simulated Approaches
|
Al-Aqqad, Hamsa
|
|
2015
|
|
3 |
p. 169-178
|
artikel
|
| 4 |
Biotechnology Industry Organization — BIO 2006
|
Bardsley-Elliot, Anne
|
|
|
|
3 |
p. 187-196
|
artikel
|
| 5 |
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
|
Krentz, Andrew J.
|
|
2014
|
|
3 |
p. 109-117
|
artikel
|
| 6 |
Content Related to Older Adults in Canadian Innovator–Drug Product Monographs: An Exploratory Analysis
|
Babadagli, Hazal E.
|
|
2016
|
|
3 |
p. 149-155
|
artikel
|
| 7 |
Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue
|
Kotecki, Nuria
|
|
2016
|
|
3 |
p. 143-147
|
artikel
|
| 8 |
Drug in Clinical Development for Hepatitis C: Summary and Table
|
|
|
2014
|
|
3 |
p. 123-134
|
artikel
|
| 9 |
Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist
|
Lewis, James H.
|
|
2013
|
|
3 |
p. 165-191
|
artikel
|
| 10 |
Drugs in Clinical Development for Psoriasis and Psoriatic Arthritis: Summary and Table
|
|
|
2013
|
|
3 |
p. 193-201
|
artikel
|
| 11 |
Drugs in Clinical Development for Pulmonary Hypertension: Summary and Table
|
|
|
2015
|
|
3 |
p. 179-182
|
artikel
|
| 12 |
Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures
|
Zografos, Laurie J.
|
|
2019
|
|
3 |
p. 235-246
|
artikel
|
| 13 |
Evaluation of Two Strategies for Community-Based Safety Monitoring during Seasonal Malaria Chemoprevention Campaigns in Senegal, Compared with the National Spontaneous Reporting System
|
Ndiaye, Jean-Louis A.
|
|
2018
|
|
3 |
p. 189-200
|
artikel
|
| 14 |
Factors Associated with Drug-Related Emergency Department Visits at a Teaching Hospital in Malaysia
|
Ab Rahman, Ab Fatah
|
|
2017
|
|
3 |
p. 175-181
|
artikel
|
| 15 |
Forum
|
|
|
2013
|
|
3 |
p. 203-213
|
artikel
|
| 16 |
Forum
|
|
|
2017
|
|
3 |
p. 183-207
|
artikel
|
| 17 |
Forum
|
|
|
2016
|
|
3 |
p. 169-182
|
artikel
|
| 18 |
Forum
|
|
|
2018
|
|
3 |
p. 219-237
|
artikel
|
| 19 |
Forum
|
|
|
2015
|
|
3 |
p. 183-192
|
artikel
|
| 20 |
Forum
|
|
|
2014
|
|
3 |
p. 135-147
|
artikel
|
| 21 |
Forum
|
|
|
2019
|
|
3 |
p. 247-256
|
artikel
|
| 22 |
Genome Editing: Promoting Responsible Research
|
Hirsch, François
|
|
2019
|
|
3 |
p. 187-191
|
artikel
|
| 23 |
Improving Asthma Outcomes in the Digital Era: A Systematic Review
|
Biblowitz, Kathleen
|
|
2018
|
|
3 |
p. 173-187
|
artikel
|
| 24 |
Incorporation of Abuse Potential Assessment into the Development of New Prescription Drugs
|
Mansbach, Robert S.
|
|
2015
|
|
3 |
p. 141-153
|
artikel
|
| 25 |
Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan
|
Tanaka, Makoto
|
|
2018
|
|
3 |
p. 201-207
|
artikel
|
| 26 |
Investigation into the Impact of Aging on Serious Adverse Events Associated with Antirheumatic Agents Using the Japanese Adverse Drug Event Report Database
|
Matsuoka, Yomei
|
|
2018
|
|
3 |
p. 209-217
|
artikel
|
| 27 |
Journal Watch
|
|
|
2013
|
|
3 |
p. 215-223
|
artikel
|
| 28 |
Journal Watch
|
|
|
2014
|
|
3 |
p. 149-161
|
artikel
|
| 29 |
Linking Death Certificates, Postmortem Toxicology, and Prescription History Data for Better Identification of Populations at Increased Risk for Drug Intoxication Deaths
|
Slavova, Svetla
|
|
2017
|
|
3 |
p. 155-165
|
artikel
|
| 30 |
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data
|
Parigi, Angelo Del
|
|
2019
|
|
3 |
p. 209-217
|
artikel
|
| 31 |
Major Pharmaceutical Conferences and Courses
|
|
|
2017
|
|
3 |
p. 209-211
|
artikel
|
| 32 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016
|
|
3 |
p. 183-185
|
artikel
|
| 33 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018
|
|
3 |
p. 239-241
|
artikel
|
| 34 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
3 |
p. 193-196
|
artikel
|
| 35 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014
|
|
3 |
p. 163-167
|
artikel
|
| 36 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013
|
|
3 |
p. 225-229
|
artikel
|
| 37 |
Major Pharmaceutical Conferences and Courses
|
|
|
2019
|
|
3 |
p. 257-259
|
artikel
|
| 38 |
Myths and Realities About Why Prescription Drug Prices in the United States Are So High
|
Lexchin, Joel
|
|
2017
|
|
3 |
p. 143-148
|
artikel
|
| 39 |
Nanoparticle-Mediated Delivery of Therapeutic Drugs
|
Ponnappan, Nisha
|
|
2015
|
|
3 |
p. 155-167
|
artikel
|
| 40 |
Nordic Health Registers as a Source for Value-Based Evidence
|
Flaten, Olav
|
|
2014
|
|
3 |
p. 119-122
|
artikel
|
| 41 |
Pharmacovigilance and Public Health Ethics
|
Callréus, Torbjörn
|
|
2013
|
|
3 |
p. 157-164
|
artikel
|
| 42 |
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures
|
Zografos, Laurie J.
|
|
2019
|
|
3 |
p. 219-233
|
artikel
|
| 43 |
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
|
Martinez-Grau, Maria Angeles
|
|
2019
|
|
3 |
p. 193-198
|
artikel
|
| 44 |
Quantitative Analysis of the Role of Patents and Drug Approvals in Drug Lifecycle Management in Japan
|
Yamanaka, Takayuki
|
|
2016
|
|
3 |
p. 157-164
|
artikel
|
| 45 |
Reflections on the Evolution of Patient Engagement in Drug Development
|
Getz, Kenneth
|
|
2019
|
|
3 |
p. 179-185
|
artikel
|
| 46 |
Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive
|
Borup, Rasmus
|
|
2019
|
|
3 |
p. 199-207
|
artikel
|
| 47 |
The Changing Face of Direct-to-Consumer Print Advertising
|
Macias, Wendy
|
|
2010
|
|
3 |
p. 165-177
|
artikel
|
| 48 |
The Francis Crick Institute: Scientific Discovery Open to Translation
|
Roblin, David
|
|
2016
|
|
3 |
p. 133-135
|
artikel
|
| 49 |
The Future of Pharmacovigilance: Proposals for More Efficient and Effective Systems-Based Approaches
|
Furlan, Giovanni
|
|
2016
|
|
3 |
p. 137-142
|
artikel
|
| 50 |
The revised Declaration of Helsinki: interpreting and implementing ethical principles in biomedical research
|
Pérez, Analia C.
|
|
|
|
3 |
p. 131-143
|
artikel
|
| 51 |
The Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and Europe
|
Marquis, Patrick
|
|
2011
|
|
3 |
p. 147-160
|
artikel
|
| 52 |
Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives
|
Bhattacharya, Mondira
|
|
2017
|
|
3 |
p. 167-174
|
artikel
|
| 53 |
Value-Based Pharmaceutical Pricing From the Patient Perspective Could Incentivize Innovation
|
Koh, Cloe Ying C.
|
|
2017
|
|
3 |
p. 149-153
|
artikel
|
Tijdschrift beschrijving